Skip to content

Analysis of the Molecular Profile of the Mixofibrosarcoma of the Extremities

Analysis of the Molecular Profile of the Mixofibrosarcoma of the Extremities: Diagnostic and Prognostic Impact

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04991883
Acronym
MFS
Enrollment
167
Registered
2021-08-05
Start date
2021-09-01
Completion date
2022-12-31
Last updated
2023-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoma,Soft Tissue

Keywords

Mixofibrosarcoma

Brief summary

Single institution case series review with a histological diagnosis of mixofibrosarcoma of the extremities from 01 Jan 1993 to 01 Dec 2017. The study will exam all the clinical, radiological, histological and immunohistochemical features of this tumour in all samples and in a limited serie of cases the presence of mutation of 50 genes cancer related.

Interventions

OTHERcase series review of clinical and histological data

We will review all the medical records, radiological imaging, and histological data of these cases. The immunohistochemical analysis of the principal alterated genes identified in this tumor will be performed.

Sponsors

Istituto Ortopedico Rizzoli
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male and female patients treated at Rizzoli Institute from 01 Jan 1993 to 01 Dec 2017 2. Diagnosis of mixofibrosarcoma of extremities 3. Histological slides/formalin-fixed paraffin-embedded tissue tumor (FFPE) blocks from archive available to perform the histology analysis and molecular analysis 4. Enough tumor biobanked material available for molecular analysis 5. Presence of the biobank signed informed consent 6. Written informed consent prior to any study-specific analysis and/or data collection

Exclusion criteria

1\) Patients with histological diagnosis different from mixofibrosarcoma of extremities

Design outcomes

Primary

MeasureTime frameDescription
disease-free survivalat baseline (Day0)identify patients with different risk classes in terms of disease-free survival (local and systemic recurrence).
overall survivalat baseline (Day0)identify patients with different risk classes in terms of overall survival.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026